In the Journals

Tranexamic acid linked with reduced blood loss among patients undergoing THA

Chad D. Watts

Recently published results showed reduced blood loss among patients who received tranexamic acid and were undergoing hip arthroplasty for acute femoral neck fracture.

Chad D. Watts, MD, and colleagues randomly assigned 138 patients who presented with a low-energy, isolated femoral neck fractures treated with either hemiarthroplasty or total hip arthroplasty (THA) within 72 hours of injury to receive tranexamic acid or a saline solution. As the primary outcome measure, researchers determined the proportion of patients who underwent blood transfusion during hospitalization. Secondary outcome measures included calculated blood loss, number of units transfused during hospitalization and incidence of adverse events at 30 days and 90 days including thromboembolic events, wound complications, reoperation, hospital readmission and all-cause mortality.

Results showed fewer patients in the tranexamic group vs. the placebo group had allogenic blood transfusions; however, this finding did not reach statistical significance. Researchers noted patients in the tranexamic group who underwent blood transfusion required less total blood product. Compared with placebo, administration of tranexamic acid significantly reduced mean calculated blood loss, according to results, with mean cumulative blood loss 242 mL lower, 294 mL lower and 305 mL lower on postoperative days 1, 2 and 3, respectively. Researchers found no differences in adverse outcomes between the two groups at 30 days and 90 days postoperatively. – by Casey Tingle

Disclosures: Watts reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.

Chad D. Watts

Recently published results showed reduced blood loss among patients who received tranexamic acid and were undergoing hip arthroplasty for acute femoral neck fracture.

Chad D. Watts, MD, and colleagues randomly assigned 138 patients who presented with a low-energy, isolated femoral neck fractures treated with either hemiarthroplasty or total hip arthroplasty (THA) within 72 hours of injury to receive tranexamic acid or a saline solution. As the primary outcome measure, researchers determined the proportion of patients who underwent blood transfusion during hospitalization. Secondary outcome measures included calculated blood loss, number of units transfused during hospitalization and incidence of adverse events at 30 days and 90 days including thromboembolic events, wound complications, reoperation, hospital readmission and all-cause mortality.

Results showed fewer patients in the tranexamic group vs. the placebo group had allogenic blood transfusions; however, this finding did not reach statistical significance. Researchers noted patients in the tranexamic group who underwent blood transfusion required less total blood product. Compared with placebo, administration of tranexamic acid significantly reduced mean calculated blood loss, according to results, with mean cumulative blood loss 242 mL lower, 294 mL lower and 305 mL lower on postoperative days 1, 2 and 3, respectively. Researchers found no differences in adverse outcomes between the two groups at 30 days and 90 days postoperatively. – by Casey Tingle

Disclosures: Watts reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.